Anavex Life Sciences Corp (NASDAQ:AVXL)

2.92
Delayed Data
As of Sep 13
 -0.07 / -2.34%
Today’s Change
1.25
Today|||52-Week Range
4.09
+87.18%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$153.7M

Company Description

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Contact Information

Anavex Life Sciences Corp.
51 West 52nd Street
New York New York 10019-6163
P:(800) 689-3939
Investor Relations:

Employees

Shareholders

Mutual fund holders8.68%
Individual stakeholders4.46%
Other institutional13.72%

Top Executives

Christopher U. MisslingPresident, CEO, Secretary & Director
Stephan ToutainSenior Vice President-Operations
Sandra BoenischPrincipal Financial Officer & Treasurer
Walter E. KaufmannChief Medical Officer
Tasos ZografidisVice President-Clinical Operations